WallStreetZenWallStreetZen

NASDAQ: LRMR
Larimar Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for LRMR

Based on 3 analysts offering 12 month price targets for Larimar Therapeutics Inc.
Min Forecast
$10.00+37.55%
Avg Forecast
$20.00+175.1%
Max Forecast
$25.00+243.88%

Should I buy or sell LRMR stock?

Based on 3 analysts offering ratings for Larimar Therapeutics Inc.
Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their LRMR stock forecasts and price targets.

LRMR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-03
lockedlocked$00.00+00.00%2024-03-15
lockedlocked$00.00+00.00%2024-02-13Find Out Why

1 of 1

Forecast return on equity

Is LRMR forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
34.02%

Forecast return on assets

Is LRMR forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

LRMR revenue forecast

What is LRMR's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$43.7M
Avg 2 year Forecast
$51.6M
Avg 3 year Forecast
$162.9M

LRMR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LRMR$7.27$20.00+175.10%Strong Buy
URGN$12.91$43.00+233.08%Buy
RNAC$25.83$45.00+74.22%Buy
VYGR$8.45$18.00+113.02%Strong Buy
TVTX$6.17$13.17+113.40%Buy

Larimar Therapeutics Stock Forecast FAQ

Is Larimar Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: LRMR) stock is to Strong Buy LRMR stock.

Out of 3 analysts, 1 (33.33%) are recommending LRMR as a Strong Buy, 2 (66.67%) are recommending LRMR as a Buy, 0 (0%) are recommending LRMR as a Hold, 0 (0%) are recommending LRMR as a Sell, and 0 (0%) are recommending LRMR as a Strong Sell.

If you're new to stock investing, here's how to buy Larimar Therapeutics stock.

What is LRMR's revenue growth forecast for 2026-2028?

(NASDAQ: LRMR) Larimar Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.99%.

Larimar Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast LRMR's revenue for 2026 to be $2,788,148,143, with the lowest LRMR revenue forecast at $2,788,148,143, and the highest LRMR revenue forecast at $2,788,148,143. On average, 2 Wall Street analysts forecast LRMR's revenue for 2027 to be $3,293,141,107, with the lowest LRMR revenue forecast at $295,403,339, and the highest LRMR revenue forecast at $6,290,878,876.

In 2028, LRMR is forecast to generate $10,392,710,549 in revenue, with the lowest revenue forecast at $7,776,189,832 and the highest revenue forecast at $13,009,231,266.

What is LRMR's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: LRMR) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is LRMR's Price Target?

According to 3 Wall Street analysts that have issued a 1 year LRMR price target, the average LRMR price target is $20.00, with the highest LRMR stock price forecast at $25.00 and the lowest LRMR stock price forecast at $10.00.

On average, Wall Street analysts predict that Larimar Therapeutics's share price could reach $20.00 by Apr 3, 2025. The average Larimar Therapeutics stock price prediction forecasts a potential upside of 175.1% from the current LRMR share price of $7.27.

What is LRMR's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: LRMR) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.